Macrophagic Myofasciitis
Immune/Antibody
W
View full entry on WUSTL Neuromuscular
antibody/infmyop.htm#Macrophagic Myofasciitis
4
Overview
From WUSTL NeuromuscularEpidemiology Most reported cases French Male = Female Onset age: 3rd to 5th Decade Disease duration: 3 to 48 months Associated with: Injections of aluminum-containing vaccines Timing: 3 months to 8 years before onset of symptoms Immunization type: Hepatitis B (86%); Tetanus (58%); Hepatitis A (19%) Pathogenesis Persistence of vaccine-derived aluminum hydroxide at site of IM injection MMF patients may be of HLA-DRB1*01 group ? Protracted low level immune stimulation due to persistence of adjuvant in antigen presenting cells Clinical Pain & Discomfort Myalgias (80%): Proximal > Distal Arthralgia
Related Conditions
Shared genesExternal Resources
Data sourced from the Washington University Neuromuscular Disease Center. For clinical use, always refer to primary sources.